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Correlations Between Management Behaviors and Financial Indicators
with FDA Compliance Leading to Medicine Shortages
Francisco Gutiérrez-Pérez, PhD
Abstract

Purpose

A series of Food and Drug Administration (FDA)
interventions and enforcement actions against
pharmaceutical manufacturers in the past 5-6 years
led to medicine shortages in the United States.
• The manufacturing shortfalls made essential
medicines unavailable for the treatment of patients.
• Manufacturing shortfalls implied that quality
management and manufacturing systems were not
empowered or adequately staffed to support the
critical functions of the pharmaceutical firms.

Problem
The general problem investigated in this study was a
significant increase in the number of pharmaceutical
firms cited for noncompliance with federal quality
guidelines.
• In the first three years of the Obama Administration,
the number of warning letters issued to
pharmaceutical firms for manufacturing and quality
problems increased to 49 letters. (Nguyen, SeoaneVazquez, Rodriguez-Monguio, & Montagne, 2013).
• In comparison, the FDA only issued nine warning
letters in the last three years of the George W. Bush
Administration (Nguyen, Seoane-Vazquez,
Rodriguez-Monguio, & Montagne, 2013).
• In a letter dated October 31, 2011, the FDA
indicated that about 54% of drug shortages were a
result of manufacturers’ quality issues (FDA, 2011).
• The lack of compliance with Current Good
Manufacturing Practices (CGMP) led to
pharmaceuticals manufacturing facility closures,
loss of revenues, certain penalty fees, loss of
reputation, and significant investments to address
remediation of their non-conformances to the FDA
regulations. (Asotra, Cossin, & Yacobi, 2012).

Determine to what extent, if any, management
behavior and financial indicators were correlated with
the compliance of FDA regulations leading to medicine
shortages.

Procedures
I selected to conduct a quantitative study.
• correlations
• regression line analyses
Study Variables

Relevant Literature
• The level of sustainability depends on the degree of
change that management embraces and accepts
(Asotra, Cossin, & Yacobi, 2012).
• As emphasized by Woodcock (2012), manufacturing
shortfalls implied that quality management and
systems were not empowered or properly staffed.
• Historical trends of drug shortages represented an
increase from 61 shortages in 2005 (Barlas, 2014)
to 251 shortages in 2011 (FDA, 2013).
Theoretical Framework
The theory of planned behavior (TPB) was used to
frame the behaviors of the pharmaceutical managers
(Ajzen, 1991).
• Central point of TPB -- a direct relationship between
intention and actual behavior.
• TPB highlights -- behavior could be explained and
behaviors are not difficult to predict.
For this study, the intention of management to comply
with the regulations of the FDA, as well as with the
financial limitations, created an excellent scenario to
examine with the TPB.

Research Questions
RQ 1: To what extent, if any, do management
behaviors correlate to compliance with FDA
regulations at the pharmaceutical firms in the USA?
RQ 2: To what extent, if any, do financial indicators
correlate to compliance with FDA regulations at the
pharmaceutical firms in the USA?
RQ 3: To what extent, if any, do financial indicators
impact compliance with FDA regulations at the
pharmaceutical firms in the USA?

• Independent Variables: Management Behaviors and
Financial Indicators
• Dependent Variable: Compliance with FDA
Regulations
• Treatment: FDA Intervention
• Scenarios: Pre-FDA and Post-FDA Intervention
Participants
• 1144 members of the International Society of
Pharmaceutical Engineers (ISPE) with job titles
representing management positions.
• Participants from public pharmaceutical companies
in the United States.
Data Collection
The complete responses from 21 participants through
133 Likert-type scales and scaled ranges were the
input to the data analysis.

Data Analysis
Correlations, aggregate comparison and Cronbach’s
alpha were utilized. ANOVA, t tests, Durbin-Watson
statistics, and collinearity statistics supported the
examination of the assumptions to establish the
generalization of the findings.

Findings

Limitations
• Only 21 out of 1144 ISPE invitees completed the
survey, possibly due to apathy for surveys, internet
firewalls, and the sensitivity of the topic of
compliance in the pharmaceutical industry.
• The length of the survey with 133 questions also
impacted the participation.

Conclusions
Consumer
Having a high level of compliance with the FDA
regulations reduces investments and compliance
expenses minimizing interruptions in the supply of
essential pharmaceutical drugs.
Stockholders
The significant correlation between stockholders’
equity and compliance, in both pre-FDA and postFDA interventions, signaled the relevance of the
firm’s compliance and the investors’ expectations.
Management
The behaviors and the decision-making processes
of the pharmaceutical manager could reinforce the
presence of effective quality systems eliminating or
minimizing medicine shortages.
Pharmaceutical Firm
The lack of compliance could impact the reputation
and the performance of the firm negatively.

Social Change Implications
• The main potential social impact was to avoid
having medicine shortages.

• The FDA intervention had a favorable influence on
the participants’ behaviors increasing the level of
compliance.

• The risk of affecting the patient health could be
minimized or eliminated by avoiding medicine
shortages.

• The TPB provided linear regression models to
predict behavior reinforcing that management could
modify behaviors to enhance future compliance.

• The study was directed to encourage managers of
pharmaceutical organizations to operate and
behave with a clear approach to compliance.

• Behaviors and financial indicators correlated with
compliance of the firm with the FDA regulations.
• The financial indicators contributed to the impact on
compliance in the regression model only during the
Pre-FDA intervention.
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